» Articles » PMID: 21922167

Emerging and Novel Therapeutic Approaches in the Treatment of Male Erectile Dysfunction

Overview
Journal Curr Urol Rep
Publisher Current Science
Specialty Urology
Date 2011 Sep 17
PMID 21922167
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Over the past few decades, a dramatic increase in our understanding of the pathophysiology of penile erection has occurred. The advent of phosphodiesterase type 5 inhibitors has revolutionized the treatment of erectile dysfunction (ED), while the introduction of modern penile prosthesis has almost completely replaced the need for vascular surgery. Despite the efficacy of current therapeutic options for ED, they are not without limitations and remain insufficient to address the growing patient population and various underlying medical conditions. Newer and novel ED therapies aspire to treat underlying microvascular abnormalities, prevent cavernosal fibrosis, promote endothelial revascularization, modulate neurohormonal pathways, and regenerate new penile tissue.

Citing Articles

A Review of Current and Emerging Therapeutic Options for Erectile Dysfunction.

Chung E Med Sci (Basel). 2019; 7(9).

PMID: 31470689 PMC: 6780857. DOI: 10.3390/medsci7090091.


Canadian consensus algorithm for erectile rehabilitation following prostate cancer treatment.

Elterman D, Petrella A, Walker L, Van Asseldonk B, Jamnicky L, Brock G Can Urol Assoc J. 2018; 13(8):239-245.

PMID: 30526799 PMC: 6737730. DOI: 10.5489/cuaj.5653.


Molecular and functional characterization of Kv 7 channels in penile arteries and corpus cavernosum of healthy and metabolic syndrome rats.

Jepps T, Olesen S, Greenwood I, Dalsgaard T Br J Pharmacol. 2016; 173(9):1478-90.

PMID: 26802314 PMC: 4831315. DOI: 10.1111/bph.13444.


Psychosocial perspectives on sexual recovery after prostate cancer treatment.

Walker L, Wassersug R, Robinson J Nat Rev Urol. 2015; 12(3):167-76.

PMID: 25753250 DOI: 10.1038/nrurol.2015.29.


Current status of penile rehabilitation after radical prostatectomy.

Kim J, Lee S Korean J Urol. 2015; 56(2):99-108.

PMID: 25685296 PMC: 4325125. DOI: 10.4111/kju.2015.56.2.99.

References
1.
Wood D, Southgate J . Current status of tissue engineering in urology. Curr Opin Urol. 2008; 18(6):564-9. DOI: 10.1097/MOU.0b013e32830f9402. View

2.
Bakircioglu M, Lin C, Fan P, Sievert K, Kan Y, Lue T . The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence. J Urol. 2001; 165(6 Pt 1):2103-9. DOI: 10.1097/00005392-200106000-00078. View

3.
Wessells H, Levine N, Hadley M, Dorr R, Hruby V . Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000; 12 Suppl 4:S74-9. DOI: 10.1038/sj.ijir.3900582. View

4.
Ciampa A, Carcereri de Prati A, Amelio E, Cavalieri E, Persichini T, Colasanti M . Nitric oxide mediates anti-inflammatory action of extracorporeal shock waves. FEBS Lett. 2005; 579(30):6839-45. DOI: 10.1016/j.febslet.2005.11.023. View

5.
Bivalacqua T, Usta M, Champion H, Leungwattanakij S, Dabisch P, McNamara D . Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res. 2004; 16(1):21-9. DOI: 10.1038/sj.ijir.3901054. View